Literature DB >> 12689711

Rapid detection of resistance against rifampicin in isolates of Mycobacterium tuberculosis from Brazilian patients using a reverse-phase hybridization assay.

Martha M de Oliveira1, Adalgiza da Silva Rocha, Maraníbia Cardoso Oelemann, Harisson M Gomes, Leila Fonseca, Angela M Werneck-Barreto, Andréia Moura Valim, Maria L Rossetti, Rudi Rossau, Wouter Mijs, Bart Vanderborght, Philip Suffys.   

Abstract

The main objective of this study was to evaluate INNO-LiPA Rif.TB and to determine the frequency of mutations in rpoB in rifampicin-resistant Mycobacterium tuberculosis isolates of Brazilian tuberculosis patients. We used the reverse hybridization assay on 113 resistant and 15 sensitive clinical isolates of M. tuberculosis and on reference strains belonging to 37 different species. All MTB complex strains and none of the other strains reacted with the MTB complex-specific probe, meaning that the assay is 100% specific and 100% sensitive for detection of strains of the MTB complex. In 80 resistant strains, mutations causing S531L (n=55), H526Y (n=9), H526D (n=12) or D516V (n=9) were detected while in 30 strains, mutations were present but their exact nature was not determined by the assay (DeltaS patterns). All sensitive strains had the sensitive genotype while among resistant isolates, a sensitive genotype was obtained in three due to the absence of mutations in the hot spot region, demonstrating an assay accuracy of 97.6% for detection of drug susceptibility. In 10 resistant cultures, two or more mutations were detected and in five, mixed sensitive and resistant genotypes were observed. The sensitivity of the assay for detection of resistant organisms in a mixture with sensitive ones were 2% and 70%, respectively, considering the appearance and disappearance of the R2 and S2 bands. The sensitivity to detect heteroresistance is similar to that of the proportion method when a specific probe for the mutation is present but the performance of the assay in the patient population will depend on the frequency of mutation distribution.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12689711     DOI: 10.1016/s0167-7012(02)00253-1

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  11 in total

1.  Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.

Authors:  Paolo Miotto; Federica Piana; Valeria Penati; Filippo Canducci; Giovanni Battista Migliori; Daniela Maria Cirillo
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

2.  Rapid detection of isoniazid resistance in Mycobacterium tuberculosis isolates by use of real-time-PCR-based melting curve analysis.

Authors:  Siyu Hu; Guoli Li; Hui Li; Xiaoli Liu; Jianjun Niu; Shengmao Quan; Feng Wang; Huixin Wen; Ye Xu; Qingge Li
Journal:  J Clin Microbiol       Date:  2014-03-05       Impact factor: 5.948

3.  Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis.

Authors:  Syed Beenish Rufai; Parveen Kumar; Amit Singh; Suneel Prajapati; Veena Balooni; Sarman Singh
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

Review 4.  Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Authors:  William A Wells; Catharina C Boehme; Frank G J Cobelens; Colleen Daniels; David Dowdy; Elizabeth Gardiner; Jan Gheuens; Peter Kim; Michael E Kimerling; Barry Kreiswirth; Christian Lienhardt; Khisi Mdluli; Madhukar Pai; Mark D Perkins; Trevor Peter; Matteo Zignol; Alimuddin Zumla; Marco Schito
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

5.  Multidrug-Resistant Mycobacterium tuberculosis of the Latin American Mediterranean Lineage, Wrongly Identified as Mycobacterium pinnipedii (Spoligotype International Type 863 [SIT863]), Causing Active Tuberculosis in South Brazil.

Authors:  Elis R Dalla Costa; Sidra E G Vasconcelos; Leonardo S Esteves; Harrison M Gomes; Lia L Gomes; Pedro Almeida da Silva; João Perdigão; Isabel Portugal; Miguel Viveiros; Ruth McNerney; Arnab Pain; Taane G Clark; Nalin Rastogi; Gisela Unis; Maria Lucia R Rossetti; Philip Noel Suffys
Journal:  J Clin Microbiol       Date:  2015-12       Impact factor: 5.948

6.  Redefining MTBDRplus test results: what do indeterminate results actually mean?

Authors:  C Nikam; R Patel; M Sadani; K Ajbani; M Kazi; R Soman; A Shetty; S B Georghiou; T C Rodwell; A Catanzaro; C Rodrigues
Journal:  Int J Tuberc Lung Dis       Date:  2016-02       Impact factor: 2.373

7.  High-resolution melting analysis for the rapid detection of fluoroquinolone and streptomycin resistance in Mycobacterium tuberculosis.

Authors:  Ann S G Lee; Danny C T Ong; Joshua C L Wong; Gilman K H Siu; Wing-Cheong Yam
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

Review 8.  A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.

Authors:  Maureen Morgan; Shriprakash Kalantri; Laura Flores; Madhukar Pai
Journal:  BMC Infect Dis       Date:  2005-07-28       Impact factor: 3.090

9.  Performance of the Genotype MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation.

Authors:  Vladyslav Nikolayevskyy; Yanina Balabanova; Tatyana Simak; Nadezhda Malomanova; Ivan Fedorin; Francis Drobniewski
Journal:  BMC Clin Pathol       Date:  2009-03-10

10.  Genetic diversity and molecular epidemiology of multidrug-resistant Mycobacterium tuberculosis in Minas Gerais State, Brazil.

Authors:  Nayanne Gama Teixeira Dantas; Phillip Noel Suffys; Wânia da Silva Carvalho; Harrison Magdinier Gomes; Isabela Neves de Almeida; Lida Jouca de Assis; Claudio José Augusto; Michel Kireopori Gomgnimbou; Guislaine Refregier; Christophe Sola; Silvana Spíndola de Miranda
Journal:  BMC Infect Dis       Date:  2015-08-01       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.